No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
10-Q: Q3 2024 Earnings Report
10-Q/A: Quarterly report (Amendment)
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements
10-Q: Q2 2024 Earnings Report
Express News | Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination With PowerUp Acquisition Corp.
10-Q: Q1 2024 Earnings Report
Unlock the Full List